Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease (clinicaltrials.gov) - Oct 17, 2026 - P2 | N=25 | Suspended | Sponsor: Northside Hospital, Inc. | Recruiting ➔ Suspended | Trial primary completion date: Dec 2026 ➔ Mar 2027
Trial primary completion date • Trial suspension • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology
|